LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of Insulet Corp. (“Insulet” or the “Company”) (NASDAQ: PODD) concerning the Company’s and its officers’ possible violations of federal securities laws.
Insulet, the maker of insulin infusion systems, posted results on April 30, 2015, after the market close, that fell below analyst expectations. The Company posted quarterly revenue of $61.2 million in the period, which did not meet an analysts survey expecting $68.3 million. For the current quarter ending in June, Insulet said it expects revenue in the range of $67 million to $70 million. Insulet also provided full-year revenue projections in the range of $305 million to $320 million.
On this news Insulet shares fell over 18%, or $5.65 per share in after-hours trading on April 30, 2015.
If you purchased shares of Insulet between February 2013 through April 30, 2015, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of Glancy Prongay & Murray LLP , 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.